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nd Outcomes in 6,427 Patients With
eart Failure and Coronary Artery Disease
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dmonton, Vancouver, and Calgary, Canada
OBJECTIVES This study was designed to examine the use of cardiovascular medications and outcomes in
patients with heart failure (HF) and renal dysfunction.
BACKGROUND Renal insufficiency is associated with poorer outcomes in patients with HF, but the
mechanisms are uncertain. In particular, the degree of therapeutic nihilism in these patients,
and whether it is appropriate, is unclear.
METHODS This was a prospective cohort study with a one-year follow-up.
RESULTS In 6,427 patients with cardiologist-diagnosed HF and angiographically proven coronary
artery disease (mean age 69 years; 65% men; one-year mortality, 10%), 39% had creatinine
clearances 60 ml/min. Patients with renal insufficiency were less likely to be prescribed
angiotensin-converting enzyme (ACE) inhibitors, beta-blockers, statins, or aspirin (all p 
0.001). However, users of aspirin (odds ratio [OR] 0.69, 95% confidence interval [CI] 0.57
to 0.85), statins (OR 0.79, 95% CI 0.64 to 0.97), and beta-blockers (OR 0.75, 95% CI 0.62
to 0.90) were less likely to die in the subsequent 12 months than nonusers, irrespective of
renal function (all OR adjusted for covariates including atherosclerotic burden and ejection
fraction). Although ACE inhibitor users with creatinine clearances 60 ml/min had lower
12-month mortality (OR 0.72, 95% CI 0.48 to 0.99), ACE inhibitor users with clearances
60 ml/min did not (OR 1.21, 95% CI 0.97 to 1.51).
CONCLUSIONS Renal insufficiency is common in patients with HF and coronary artery disease, and these
patients have more advanced coronary atherosclerosis. Patients with renal insufficiency are less
likely to be prescribed efficacious therapies, but have better outcomes if they receive these
medications. (J Am Coll Cardiol 2004;44:1587–92) © 2004 by the American College of
ublished by Elsevier Inc. doi:10.1016/j.jacc.2004.06.072Cardiology Foundation
c
w
p
a
a
e
F
h
H
w
t
a
c
M
W
O
B
s
aenal insufficiency is common in patients with heart failure
HF) and is an adverse prognostic factor (1–7). Theories
dvocating increased risk when HF and renal disease coexist
nclude a higher burden of comorbidities, increased toxici-
ies from diagnostic procedures or therapies, accelerated
therosclerosis, or less use of proven efficacious therapies in
atients with both conditions (8). Of note, this last expla-
ation rests upon the assumption that trial-proven therapies
such as angiotensin-converting enzyme [ACE] inhibitors,
eta-blockers, aspirin, and statins in HF patients with
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ccepted June 22, 2004.oronary disease) will improve outcomes even in patients
ith renal insufficiency. However, until trials that include
atients with anything more than mild renal insufficiency
re conducted, this assumption remains largely untested,
nd we must rely on observational studies to estimate the
ffectiveness and safety of therapies in these patients (9).
ew such studies have been published and, of those that
ave, all but one (our previous study of 754 patients with
F from one center) (1) focused exclusively on patients
ith acute coronary syndromes (10–15). Thus, we designed
his study to examine the use of cardiovascular medications
nd outcomes in patients with HF, coronary disease, and
oncomitant renal insufficiency.
ETHODS
e combined data from the Alberta Provincial Program for
utcome Assessment in Coronary Heart Disease and the
ritish Columbia Cardiac Registry; these prospective cohort
tudies compile data from all patients undergoing coronary
ngiography in Alberta and British Columbia (two Canadian
rovinces with a total population of 7.25 million in 2002). A
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Renal Insufficiency, Therapy, and Outcomes in CHF October 19, 2004:1587–92ull description of these datasets (including the variables col-
ected and definitions used) has been published previously (16).
We restricted this analysis to patients with a diagnosis of
F assigned by their attending cardiologist before under-
oing angiography who subsequently had coronary artery
isease (CAD) (defined as 50% stenosis in at least one
essel) proven on angiography. Glomerular filtration rate
as estimated using the previously validated Cockcroft-
ault formula with pre-catheterization serum creatinines,
nd patients were stratified into three groups: creatinine
learance 60 ml/min, 30 to 59 ml/min, and 30 ml/min
17).
tatistical analysis. Baseline characteristics of the study
atients (classified into the three renal function strata) and
heir prescribed medications were compared by chi-square
ests for dichotomous variables and analysis of variance for
ontinuous variables. One-year crude mortality rates were
alculated for patients who were/were not prescribed ACE
nhibitors, aspirin, beta-blockers, and statins. To adjust for
ifferences in baseline clinical characteristics and concomi-
ant medication use, multiple logistic regression analysis
ith the backward stepwise selection technique was done to
xamine prognostic factors for one-year mortality, selecting
ll clinically important variables and other prespecified
actors with p  0.25 on bivariate analyses and a prevalence
f at least 1%, and accepting statistical significance at p 
.05. All first-order interactions were tested for statistical
nd clinical significance in the multivariate model (statistical
ignificance was defined as p  0.05; clinical significance
as defined a priori as interaction ratios of1.25 or0.80)
18). An interaction ratio compares the effects of a treat-
ent in the presence and absence of the other treatment:
nteraction ratios above 1.0 indicate synergy and interaction
atios below 1.0 indicate antagonism (18). Those factors
hat were independently associated with mortality in the
ntire cohort were included in logistic regression models
and, in a sensitivity analysis, Cox proportional hazards
odels) for each of the renal function strata to determine
he associations of ACE inhibitors, beta-blockers, aspirin,
nd statins with mortality in each stratum.
ESULTS
he study cohort consisted of 6,427 patients with
ardiologist-diagnosed HF and angiographically proven
AD: 47% of angiograms were done electively and 53%
Abbreviations and Acronyms
ACE  angiotensin-converting enzyme
CAD  coronary artery disease
CI  confidence interval
HF  heart failure
LV  left ventricular
OR  odds ratioere done for acute coronary syndromes. Mean age was 69 lears, and 10% of patients were older than 80 years at
aseline (Table 1).
Three percent of the patients had end-stage renal disease
equiring dialysis, and 39% had creatinine clearances 60
l/min. One-year mortality was 10%, with higher death
ates in women (14% vs. 8% in men, p  0.0001) and older
atients (6% in patients 65 years, 13% in those aged 65 to
0 years, and 22% in those 80, p  0.0001). There was
lso a clear gradient in mortality across renal function strata:
% in those with creatinine clearance 60 ml/min, 15% in
hose with clearances of 30 to 59 ml/min, and 28% in those
ith clearances 30 ml/min (p  0.001). There were also
radients in medication use, with lower prescription rates
or ACE inhibitors, beta-blockers, statins, and aspirin with
ore advanced renal insufficiency (Table 1). Patients with
ore advanced renal insufficiency had more comorbidities,
reater coronary atherosclerotic burden, and lower ejection
ractions (Table 1).
The crude mortality rates were significantly lower for
sers of beta-blockers, statins, and aspirin than for nonusers,
rrespective of renal function (Figs. 1 and 2). The ACE
nhibitors were associated with improved survival in patients
ith creatinine clearances 60 ml/min (Fig. 1), but not in
hose patients with clearances 60 ml/min (Fig. 2).
The multivariate predictors of one-year mortality are
utlined in Table 2. Analyses of the Wald statistics revealed
hat the two most powerful prognostic factors were age and
reatinine clearance; indeed, renal function was a stronger
redictor of outcomes in this cohort of patients with
schemic HF than was coronary anatomy (Wald statistic 53
s. 34). The one-year mortality risk increased by 0.2% for
very mol/l increase in serum creatinine.
Analyses adjusted for the variables in Table 2 (with the
xception of serum creatinine) confirmed that use of beta-
lockers, ACE inhibitors, statins, and aspirin were all
ssociated with statistically significant better one-year sur-
ival in patients with HF, CAD, and a creatinine clearance
60 ml/min (Table 3). However, although statins and
spirin were also associated with improved survival in those
atients with creatinine clearances of 60 ml/min (and
eta-blockers were associated with a trend towards a survival
enefit [odds ratio (OR) 0.85, 95% confidence interval (CI)
.68 to 1.07]), ACE inhibitors were not (mortality OR
.21, 95% CI 0.97 to 1.51). Although the interaction
etween ACE inhibitors and aspirin was not significant in
he entire cohort (p  0.13), there was a strong trend for a
egative interaction on survival in those patients with
reatinine clearance 60 ml/min that met our a priori
efinition of clinical significance (p  0.09, OR for inter-
ction term 0.56, 95% CI 0.28 to 1.11). There were no
ignificant interactions between any of the other medica-
ions of interest, degree of renal function, and mortality.
The Cox proportional hazards analyses (adjusting for the
ariables in Table 2) confirmed the findings from our
ogistic regression analyses (Table 3).
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his study provides data on four key questions about the
nterplay among renal dysfunction, ischemic HF, and car-
iovascular pharmacotherapeutics.
First, we found that 39% of patients with HF and CAD
ad creatinine clearances 60 ml/min, corresponding to at
east moderate renal insufficiency. This prevalence is con-
istent with the 38% reported in a retrospective cohort study
f 665 patients with HF admitted to community hospitals
n a single American state (7) and is substantially higher
han that reported in the major HF trials (2).
Second, we confirmed the findings from multiple other
tudies that, even after adjusting for the higher burden of
omorbidities, renal dysfunction is a powerful independent
isk factor for mortality in patients with HF (1–7). How-
ver, because we had data on coronary anatomy and ejection
ractions, we were able to extend the current evidence base
n demonstrating that the adverse prognostic influence of
able 1. Characteristics of Patients With Cardiologist-Assigned
ngiography
Entire Cohort
(n  6,427)
>60 ml/min
(n  3,914)
ean age (SD) 69 (11) 63 (10)
en, no. (%) 4,205 (65%) 2,874 (73%)
omorbidities
Hypertension 2,487 (39%) 1,323 (34%)
Hyperlipidemia 2,399 (37%) 1,491 (38%)
Diabetes mellitus 1,322 (21%) 717 (18%)
Peripheral vascular disease 669 (10%) 302 (8%)
Cerebrovascular disease 516 (8%) 224 (6%)
Current smoker 861 (13%) 618 (16%)
COPD 869 (14%) 423 (11%)
Malignancy 309 (5%) 133 (3%)
Prior myocardial infarct 2,168 (34%) 1,192 (30%)
Prior CABG 572 (9%) 290 (7%)
Prior PCI 117 (2%) 55 (1%)
edications
Aspirin 4,706 (73%) 2,946 (75%)
ACE inhibitor or ARB 3,698 (58%) 2,228 (56%)
Beta-blocker 3,628 (56%) 2,287 (58%)
Statin 2,545 (40%) 1,669 (43%)
Thienopyridine 1,634 (25%) 1,062 (27%)
Long-acting nitrates 2,458 (38%) 1,346 (35%)
Warfarin 1,880 (29%) 1,119 (29%)
Calcium channel blocker 1,419 (22%) 777 (20%)
oronary anatomy
1-vessel disease 1,965 (31%) 1,331 (34%)
2-vessel disease 967 (15%) 604 (15%)
3-vessel disease 1,434 (22%) 844 (22%)
Proximal left anterior
descending involvement
1,335 (21%) 755 (19%)
Left main disease 726 (11%) 380 (10%)
Myocardium at risk,
mean % (SD)
55% (33%) 52% (32%)
LVEF, mean (SD) 37 (18) 39 (15)
ata are presented as frequency (% of column total) unless otherwise stated.
ACE angiotensin-converting enzyme; ARB angiotensin receptor blocker; CA
left ventricular ejection fraction; PCI  percutaneous coronary intervention.enal dysfunction is independent of atherosclerotic burden fnd left ventricular (LV) systolic function. Thus, of the
ultiple theories offered to explain the excess risks in
ardiac patients with renal disease (8), our data cast doubt
n suppositions that this is merely due to comorbidities,
ore advanced coronary atherosclerosis, or poorer LV
unction in renal patients.
Third, we have confirmed in a large and heterogeneous
ample of patients with ischemic HF that prescription rates
or ACE inhibitors, beta-blockers, statins, and aspirin are
nversely related to renal function. The underuse of medi-
ations in subgroups of patients excluded from the relevant
rials is a common finding in health services research, and
gain serves to emphasize the importance of observational
tudies in determining whether these prescribing patterns
re appropriate.
To that end, the fourth important finding from our study
s the association between medications and outcomes that
e demonstrated in patients with varying degrees of renal
nosis of Heart Failure and Coronary Artery Disease Proven on
Creatinine Clearance
p Value for
Comparisons Across
Renal Function Strata
30 to 59 ml/min
(n  2,047)
<30 ml/min
(n  466)
74 (8) 73 (11) 0.001
1,134 (55%) 197 (42%) 0.001
894 (44%) 270 (58%) 0.001
728 (36%) 180 (39%) 0.08
442 (22%) 163 (35%) 0.001
268 (13%) 99 (21%) 0.001
209 (10%) 83 (18%) 0.001
197 (10%) 46 (10%) 0.001
340 (17%) 106 (23%) 0.001
136 (7%) 40 (9%) 0.001
767 (37%) 209 (45%) 0.001
219 (11%) 63 (14%) 0.001
47 (2%) 15 (3%) 0.009
1,446 (71%) 314 (67%) 0.001
1,228 (60%) 242 (52%) 0.006
1,099 (54%) 242 (52%) 0.001
716 (35%) 160 (34%) 0.001
477 (23%) 95 (20%) 0.001
891 (44%) 221 (47%) 0.001
612 (30%) 149 (32%) 0.001
497 (24%) 145 (31%) 0.001
529 (26%) 105 (23%) 0.001
304 (15%) 59 (13%) 0.27
466 (23%) 124 (27%) 0.04
465 (23%) 115 (25%) 0.001
283 (14%) 63 (14%) 0.001
57% (33%) 59% (32%) 0.001
36 (19) 28 (24) 0.001
coronary artery bypass graft; COPD chronic obstructive pulmonary disease; LVEFDiagunction (all results adjusted for covariates). First, we found
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Renal Insufficiency, Therapy, and Outcomes in CHF October 19, 2004:1587–92hat aspirin use is associated with an approximately 25%
ower mortality rate in patients with ischemic HF irrespec-
ive of renal function; this is similar to the survival benefits
bserved in patients at high risk for cardiovascular events,
he vast majority of whom had normal renal function (19).
econd, we found that statin users had lower mortality rates
han nonusers in all three renal function strata; this echoes
subgroup analysis from the Cholesterol and Recurrent
vents Trial (20). Third, consistent with the results of
ystolic HF trials, we found that in patients with creatinine
learance 60 ml/min, beta-blocker users had 46% fewer
eaths than nonusers (21). We also found that beta-blocker
sers with creatinine clearances between 30 and 59 ml/min
ad better outcomes, echoing the results of subgroup
nalyses from the Cardiac Insufficiency Bisoprolol Study
CIBIS) II and the Cooperative Cardiovascular Project
22,23). In our cohort, there were too few events in patients
ith creatinine clearances 30 ml/min to make any defin-
tive conclusions, although others have reported that beta-
lockers are associated with significant survival benefits after
cute myocardial infarction in patients with dialysis-
ependent end-stage renal disease (10,11).
Finally, we found that, in patients with creatinine clear-
igure 1. Crude one-year mortality rates in 3,914 patients with cardiologist-
ssigned diagnosis of heart failure, coronary artery disease proven by
ngiography, and creatinine clearance 60 ml/min. p values are for each
airwise comparison (i.e., crude mortality rates in users vs. nonusers for
ach of the medications of interest). White bars  user; black bars 
onuser. ACE  angiotensin-converting enzyme inhibitor; ASA 
spirin.
igure 2. Crude one-year mortality rates in 2,513 patients with cardiologist-
ssigned diagnosis of heart failure, coronary artery disease proven by
ngiography, and creatinine clearance 60 ml/min. The p values are for
ach pairwise comparison (i.e., crude mortality rates in users vs. nonusersC
or each of the medications of interest). White bars  user; black bars 
onuser. Abbreviations as in Figure 1.nces60 ml/min, ACE inhibitor users had lower one-year
ortality rates: the 28% relative reduction we found is
onsistent with the data from the ACE inhibitor trials (24).
owever, we did not find lower death rates with ACE
nhibitor use in patients with creatinine clearances 60
l/min. Although this appears to be contrary to reports
rom the Cooperative Cardiovascular Project and the Heart
utcomes Prevention Evaluation (HOPE) study (23,25),
e believe the explanation may lie in a possible negative
nteraction between aspirin and ACE inhibitors in patients
ith renal insufficiency (which has been reported in other
ohorts) (13,26). Indeed, aspirin in the dose prescribed in
ur cohort (325 mg daily) does inhibit renal prostacyclin
roduction and endothelial cyclooxygenase and thus may
ncrease vascular tone and LV filling pressures (27,28);
lthough this may have little effect in patients with pre-
erved renal function, these mechanisms may well attenuate
ome of the benefits of ACE inhibitors in patients with
ecreased renal perfusion. Although a systematic review of
ix large ACE inhibitor trials reported a nonsignificant
egative interaction between ACE inhibitors and aspirin (p
0.07), the trials included in that systematic review
ncluded very few patients with serum creatinine 175
mol/l (24). On the other hand, our study and the others
eporting a negative interaction (13,26) included patients
ith moderate or severe renal insufficiency, many of whom
ere treated with lower doses of ACE inhibitors and higher
oses of aspirin than employed in the meta-analyzed trials
28). Although the Warfarin and Antiplatelet Therapy in
able 2. Multivariate Predictors of One-Year Mortality
Variable p Value
Odds Ratio
(95% Confidence Interval)
ge (per yr) 0.001 1.05 (1.04–1.06)
reatinine clearance 0.001
30 ml/min 3.19 (2.16–4.72)
30–59 ml/min 1.49 (1.11–2.00)
60 ml/min Referent
atheterization findings 0.001
Single-vessel disease Referent
Two-vessel disease 1.22 (0.86–1.74)
Proximal left anterior
descending lesion
1.71 (1.25–2.34)
Three-vessel disease 1.85 (1.36–2.52)
Left main lesion 2.36 (1.69–3.30)
iabetes mellitus 0.001 1.64 (1.34–2.01)
OPD 0.003 1.41 (1.12–1.76)
eripheral vascular disease 0.01 1.38 (1.08–1.78)
ale gender 0.002 1.50 (1.16–1.93)
spirin 0.001 0.69 (0.57–0.85)
eta-blockers 0.002 0.75 (0.62–0.90)
tatins 0.02 0.79 (0.64–0.97)
CE inhibitors 0.78 0.97 (0.81–1.16)
he variables included in the first step of these multivariate analyses were: age, gender,
reatinine clearance, pulmonary disease, cerebrovascular disease, diabetes mellitus,
yperlipidemia, malignancy, smoking status, prior coronary artery bypass surgery,
rior myocardial infarction, prior percutaneous intravascular revascularization, periph-
ral vascular disease, ACE inhibitor, beta-blocker, aspirin, calcium channel blocker,
hienopyridine, and cardiac catheterization results.
Abbreviations as in Table 1.hronic Heart failure (WATCH) trial reported excess HF
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October 19, 2004:1587–92 Renal Insufficiency, Therapy, and Outcomes in CHFospitalizations in aspirin-treated patients (88% of whom
ere taking ACE inhibitors), there were too few patients
ith moderate or severe renal insufficiency to definitively
nswer the ACE inhibitor-aspirin interaction question.
ntil further trials are done, observational studies with
igorous adjustment for measured covariates remain the best
vidence that can be brought to bear on this question.
Although our study reports on a large, well-
ategorized, consecutively enrolled, and heterogeneous
ohort with ischemic cardiomyopathy who are similar to
F cohorts recruited in population-based studies (29),
e acknowledge that these patients are likely healthier
han other ischemic cardiomyopathy patients who were
ot referred for angiography. Indeed, the 10% one-year
ortality in this cohort is substantially lower than the
9% we found in a population-based cohort of patients
ith HF from the same locale (30). However, we believe
his selection bias does not affect analyses of the associ-
tion among renal function, medication use, and out-
omes. There are some other limitations to our study. For
ne, we only have prescribing data at baseline. However,
ny medication changes or noncompliance would bias our
tudy towards the null hypothesis (by clouding any
ssociations between prescribed medications and out-
omes). Second, we relied on baseline serum creatinine to
alculate each patient’s creatinine clearance, which might
ave either underestimated (in those with elevated cre-
tinine due to acute hemodynamic disturbances) or over-
stimated (in those with progressive renal failure due to
ontrast-induced nephropathy) kidney function during
ollow-up. However, this would also have introduced a
ull bias into our study, leading to an underestimation of
he magnitude of the association between renal function
nd outcomes. Third, we do not have any data on
nmeasured confounders such as biomarkers (parathyroid
ormone, C-reactive protein, and so on); studies exam-
ning changes in these levels and subsequent clinical
utcomes are clearly needed in patients with/without
able 3. Adjusted All-Cause Mortality Risks With Prescribed M
Entire Cohort >60
eta-blockers
OR (95% CI) 0.75 (0.62–0.90) 0.54 (
HR (95% CI) 0.76 (0.67–0.85) 0.61 (
CE inhibitors
OR (95% CI) 0.97 (0.81–1.16) 0.72 (
HR (95% CI) 0.95 (0.85–1.06) 0.78 (
spirin
OR (95% CI) 0.69 (0.57–0.85) 0.63 (
HR (95% CI) 0.78 (0.69–0.89) 0.71 (
tatins
OR (95% CI) 0.79 (0.64–0.97) 0.73 (
HR (95% CI) 0.84 (0.74–0.95) 0.84 (
dds ratios (OR) are the results of the logistic regression analyses; hazards ratios (H
nalyses are those listed in Table 2 (except for creatinine).
ACE  angiotensin-converting enzyme; CI  confidence interval.enal insufficiency. Fourth, although the Modification of Viet in Renal Disease (MDRD) equation is gaining
opularity for the estimation of renal function, we used
he Cockcroft-Gault equation in this study because it has
een validated in the elderly and it performs better than
he MDRD equation in subjects with normal serum
reatinine, who made up nearly two-thirds of our cohort
31). Fifth, given the reported associations between
nemia and poor outcome in patients with HF (30), it is
nfortunate that we did not have hemoglobin data for
hese patients. However, we have previously shown in a
ohort of 754 patients followed at a specialized clinic that
enal insufficiency is an independent prognostic factor
ven after adjusting for hemoglobin values (1).
In conclusion, we found that renal insufficiency is com-
on in patients with HF and CAD, and that it is a powerful
nd independent prognostic factor (even after adjusting for
aseline differences in atherosclerotic burden and LV sys-
olic function). We also demonstrated that ACE inhibitors,
eta-blockers, statins, and aspirin were prescribed less often
or patients with more advanced renal insufficiency, but that
sers of aspirin, statins, and beta-blockers had better sur-
ival rates than nonusers across the full spectrum of renal
unction. However, whereas ACE inhibitor users with
reatinine clearances 60 ml/min had better survival rates,
CE inhibitors were not associated with reduced mortality
n patients with creatinine clearances 60 ml/min. This
pparent lack of benefit from ACE inhibitors in patients
ith moderate to severe renal insufficiency may be due to a
linically significant negative interaction between ACE
nhibitors and aspirin in patients with reduced renal perfu-
ion; however, this hypothesis needs to be tested in other
atasets.
cknowledgments
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0.99) 1.15 (0.88–1.49) 1.10 (0.69–1.73)
0.95) 0.95 (0.80–1.14) 1.23 (0.94–1.61)
0.89) 0.75 (0.56–0.99) 0.76 (0.46–1.25)
0.87) 0.81 (0.67–0.98) 0.84 (0.64–1.11)
1.01) 0.81 (0.60–1.10) 0.96 (0.57–1.63)
1.03) 0.86 (0.71–1.04) 0.85 (0.63–1.13)
the results of the Cox proportional hazards analyses. The covariates for both sets ofedica
ml/m
0.39–
0.50–
0.48–
0.65–
0.45–
0.58–
0.52–
0.69–
R) areancouver General, Royal Columbian, Royal Jubilee,
K
f
B
R
2
E
u
R
1
1
1
1
1
1
1
1
1
1
2
2
2
2
2
2
2
2
2
2
3
3
A
i
W
D
M
1592 Ezekowitz et al. JACC Vol. 44, No. 8, 2004
Renal Insufficiency, Therapy, and Outcomes in CHF October 19, 2004:1587–92elowna, and Lion’s Gate Hospitals in British Columbia
or their efforts in data collection for the APPROACH and
C Cardiac Registries.
eprint requests and correspondence: Dr. Finlay A. McAlister,
E3.24 WMC, University of Alberta Hospital, 8440 112th Street,
dmonton, Alberta, Canada T6G 2R7. E-mail: Finlay.McAlister@
alberta.ca.
EFERENCES
1. McAlister FA, Ezekowitz J, Tonelli MR, Armstrong PW. Renal
insufficiency and heart failure: prognostic and therapeutic implications
from a prospective cohort study. Circulation 2004;109:1004–9.
2. Dries DL, Exner DV, Domanski MJ, Greenberg B, Stevenson LW.
The prognostic implications of renal insufficiency in asymptomatic and
symptomatic patients with left ventricular systolic dysfunction. J Am
Coll Cardiol 2000;35:681–9.
3. Hillege HL, Girbes AR, de Kam PJ, et al. Renal function, neurohor-
monal activation, and survival in patients with chronic heart failure.
Circulation 2000;102:203–10.
4. Al-Ahmad A, Rand WM, Manjunath G, et al. Reduced kidney
function and anemia as risk factors for mortality in patients with left
ventricular dysfunction. J Am Coll Cardiol 2001;38:955–62.
5. Mahon NG, Blackstone EH, Francis GS, Starling RC, Young JB,
Lauer MS. The prognostic value of estimated creatinine clearance
alongside functional capacity in ambulatory patients with chronic
congestive heart failure. J Am Coll Cardiol 2002;40:1106–13.
6. Kearney MT, Fox KA, Lee AJ, et al. Predicting death due to
progressive heart failure in patients with mild-to-moderate chronic
heart failure. J Am Coll Cardiol 2002;40:1801–8.
7. McClellan WM, Flanders WD, Langston RD, Jurkovitz C, Presley R.
Anemia and renal insufficiency are independent risk factors for death
among patients with congestive heart failure admitted to community
hospitals: a population-based study. J Am Soc Nephrol 2002;13:1928–36.
8. McCullough PA. Cardiorenal risk: an important clinical intersection.
Rev Cardiovasc Med 2002;3:71–6.
9. Shlipak MG. Heart failure pharmacotherapy in patients with renal
insufficiency. Ann Intern Med 2003;138:917–24.
0. McCullough PA, Sandberg KR, Borzak S, Hudson MP, Garg M,
Manley HJ. Benefits of aspirin and beta-blockade after myocardial
infarction in patients with chronic kidney disease. Am Heart J
2002;144:226–32.
1. Berger AK, Duval S, Krumholz HM. Aspirin, beta-blocker, and
angiotensin-converting enzyme inhibitor therapy in patients with
end-stage renal disease and an acute myocardial infarction. J Am Coll
Cardiol 2003;42:201–8.
2. Shlipak MG, Heidenreich PA, Noguchi H, Chertow GM, Browner
WS, McClellan MB. Association of renal insufficiency with treatment
and outcomes after myocardial infarction in elderly patients. Ann
Intern Med 2002;137:555–62.
3. Frances CD, Noguchi H, Massie BM, Browner WS, McClellan M.
Are we inhibited? Renal insufficiency should not preclude the use of
ACE inhibitors for patients with myocardial infarction and depressed
left ventricular function. Arch Intern Med 2000;160:2645–50.
4. Wright RS, Reeder GS, Herzog CA, et al. Acute myocardial infarc-
tion and renal dysfunction: a high risk combination. Ann Intern Med
2002;137:563–70.
5. Freeman RV, Mehta RH, Al Badr W, Cooper JV, Kline-Rogers E,
Eagle KA. Influence of concurrent renal dysfunction on outcomes of
patients with acute coronary syndromes and implications of the use of
glycoprotein IIb/IIIa inhibitors. J Am Coll Cardiol 2003;41:718–24. G6. Ghali WA, Faris PD, Galbraith PD, et al., for the APPROACH
Investigators. Sex differences in access to coronary revascularization
after cardiac catheterization. Ann Intern Med 2002;136:723–32.
7. Cockcroft DW, Gault MH. Prediction of creatinine clearance from
serum creatinine. Nephron 1976;16:31–41.
8. McAlister FA, Straus SE, Sackett DL, Altman DG. Analysis and
reporting of factorial trials. A systematic review. JAMA 2003;289:
2545–53.
9. Antiplatelet Trialists’ Collaboration. Collaborative meta-analysis of
randomised trials of antiplatelet therapy for prevention of death,
myocardial infarction and stroke in high risk patients. BMJ 2002;324:
71–86.
0. Tonelli M, Moyé L, Sacks F, Kiberd B, Curhan G. Pravastatin for
secondary prevention of cardiovascular events in mild chronic renal
insufficiency. Ann Intern Med 2003;138:98–104.
1. Brophy JM, Joseph L, Rouleau JL. Beta-blockers in congestive heart
failure. A Bayesian meta-analysis. Ann Intern Med 2001;134:550–60.
2. Erdmann E, Lechat P, Verkenne P, et al. Results from post-hoc
analyses of the CIBIS II trial: effect of bisoprolol in high-risk patient
groups with chronic heart failure. Eur J Heart Fail 2001;3:469–79.
3. Shlipak MG, Browner WS, Noguchi H, Massie B, Frances CD,
McClellan M. Comparison of the effects of angiotensin converting-
enzyme inhibitors and beta-blockers on survival in elderly patients
with reduced left ventricular function after myocardial infarction. Am J
Med 2001;110:425–33.
4. Teo KK, Yusuf S, Pfeffer M, et al., for the ACE Inhibitors Collabo-
rative Group. Effects of long-term treatment with angiotensin con-
verting enzyme inhibitors in the presence or absence of aspirin: a
systematic review. Lancet 2002;360:1037–43.
5. Mann JFE, Gerstein HC, Pogue J, Bosch J, Yusuf S, for the HOPE
Investigators. Renal insufficiency as a predictor of cardiovascular
outcomes and the impact of ramipril: the HOPE randomized trial.
Ann Intern Med 2001;134:629–36.
6. Nguyen KN, Aurnes I, Kjekshus J. Interaction between enalapril and
aspirin on mortality after acute myocardial infarction: subgroup anal-
ysis of the Cooperative New Scandinavian Enalapril Survival Study II
(CONSENSUS II). Am J Cardiol 1997;79:115–9.
7. Meune C, Mahe I, Mourad JJ, et al. Aspirin alters arterial function in
patients with chronic heart failure treated with ACE inhibitors: a
dose-mediated deleterious effect. Eur J Heart Failure 2003;5:271–9.
8. Meune C, Mahe I, Mouradd JJ, et al. Interaction between
angiotensin-converting enzyme inhibitors and aspirin: a review. Eur
J Clin Pharmacol 2000;56:609–20.
9. Krum H, Gilbert RE. Demographics and concomitant disorders in
heart failure. Lancet 2003;362:147–58.
0. Ezekowitz JA, McAlister FA, Armstrong PW. Anemia is common in
heart failure and is associated with poor outcomes: insights from a
cohort of 12,065 patients with new onset heart failure. Circulation
2003;107:223–5.
1. Bostom AG, Kronenberg F, Ritz E. Predictive performance of renal
function equations for patients with chronic kidney disease and normal
serum creatinine levels. J Am Soc Nephrol 2002;13:2140–4.
PPENDIX
The members of the APPROACH Steering Committee
nclude Dr. William Hui (Chair), Dr. Merril Knudtson, Dr.
illiam Ghali, Dr. Stephen Archer, Dr. Michael Curtis,
r. Michelle Graham, Dr. Arvind Koshal, Dr. Andrew
aitland, Dr. Brent Mitchell, Dr. Ross Tsuyuki, Diane
albraith, Colleen Norris, and Karen Sutherland.
